QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
Log in
CVE:DMA

DiaMedica Therapeutics Inc. (DMA.V) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume27,250 shs
Average Volume6,619 shs
Market CapitalizationC$36.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-763-4965454
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$503,657.00
Book ValueC$0.17 per share

Profitability

Miscellaneous

Market CapC$36.38 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DMA News and Ratings via Email

Sign-up to receive the latest news and ratings for DMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DiaMedica Therapeutics Inc. (DMA.V) (CVE:DMA) Frequently Asked Questions

What stocks does MarketBeat like better than DiaMedica Therapeutics Inc. (DMA.V)?

Wall Street analysts have given DiaMedica Therapeutics Inc. (DMA.V) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DiaMedica Therapeutics Inc. (DMA.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of DiaMedica Therapeutics Inc. (DMA.V)'s key competitors?

Who are DiaMedica Therapeutics Inc. (DMA.V)'s key executives?

DiaMedica Therapeutics Inc. (DMA.V)'s management team includes the following people:
  • Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)
  • Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 58)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49)

What is DiaMedica Therapeutics Inc. (DMA.V)'s stock symbol?

DiaMedica Therapeutics Inc. (DMA.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "DMA."

How big of a company is DiaMedica Therapeutics Inc. (DMA.V)?

DiaMedica Therapeutics Inc. (DMA.V) has a market capitalization of C$0.00 and generates C$503,657.00 in revenue each year.

What is DiaMedica Therapeutics Inc. (DMA.V)'s official website?

The official website for DiaMedica Therapeutics Inc. (DMA.V) is www.diamedica.com.

How can I contact DiaMedica Therapeutics Inc. (DMA.V)?

DiaMedica Therapeutics Inc. (DMA.V)'s mailing address is 2 Carlson Pkwy N # N165, MINNEAPOLIS, MN 55447-4466, United States. The company can be reached via phone at +1-763-4965454.

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.